Roginolisib

Ocular Melanoma

iOncturaSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

10 Active assets in the Ocular Melanoma cohort.

Asset / Sponsor	Phase	Rating
Ipilimumab University of Michigan Rogel Cancer Center	Phase 2	BB
BELZUPACAP SAROTALOCAN Aura Biosciences	Phase 2	BB
Polyiclc Craig L Slingluff, Jr	Phase 2	B
Nivolumab University of Michigan Rogel Cancer Center	Phase 2	B
Aflibercept Centre Hospitalier Universitaire de Nice	Phase 3	B

View all 25 →

Same molecule, other indications

Roginolisib is also rated in:

uveal melanomaDormant

B

Indicative ·

58 / 100

peripheral T-cell lymphoma, not otherwise specifiedDormant

CCC

Indicative ·

48 / 100

non-small cell lung carcinomaDormant

CC

Indicative ·

46 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.